National Cancer Institute

MAC24

NCT02954874

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

n/a

Line of Therapy

Disease Stage.png

Any Stage

Disease Stage

Target.png

Biomarker(s)

TNBC

Investigational

Product

Pembrolizumab

Treatment Arms

o Arm I (observation)

o Arm II (pembrolizumab)